The clinical effectiveness and cost-effectiveness of enzyme replacement therapy for Gaucher's disease: a systematic review

The clinical effectiveness and cost-effectiveness of enzyme replacement therapy for Gaucher's disease: a systematic review

Show other versions (2)

The aim of this review is to determine the clinical effectiveness and cost-effectiveness of enzyme replacement therapy (ERT) in the treatment of symptomatic Gaucher's disease. Major electronic databases were searched from their inception to August 2003; and updated from January 2003 to July/Aug...

Full description

Bibliographic Details
Main Authors:	Connock, M, Burls, A, Frew, E, Fry-Smith, A, Juarez-Garcia, A, McCabe, C, Wailoo, A, Abrams, K, Cooper, N, Sutton, A, O'Hagan, A, Moore, D
Format:	Journal article
Language:	English
Published:	2006

Similar Items

The clinical effectiveness and cost-effectiveness of enzyme replacement therapy for Gaucher's disease: a systematic review.
by: Connock, M, et al.
Published: (2006)

The clinical effectiveness and cost-effectiveness of enzyme replacement therapy for Gaucher's disease: a systematic review.
by: Connock, M, et al.
Published: (2006)

Switching between Enzyme Replacement Therapies and Substrate Reduction Therapies in Patients with Gaucher Disease: Data from the Gaucher Outcome Survey (GOS)
by: Derralynn A. Hughes, et al.
Published: (2022-08-01)

MiRNA Expression in Patients with Gaucher Disease Treated with Enzyme Replacement Therapy
by: Łukasz Pawliński, et al.
Published: (2020-12-01)

Enzyme replacement therapy in type 1 Gaucher disease and a review of the literature
by: Gökhan Kabaçam, et al.
Published: (2010-09-01)

Enzyme replacement therapy in type 1 Gaucher disease and a review of the literature
by: Gökhan Kabaçam, et al.
Published: (2010-10-01)

A systematic review of effectiveness and economic evaluation of new drug treatments for juvenile idiopathic arthritis: etanercept.
by: Cummins, C, et al.
Published: (2002)

A systematic review of effectiveness and economic evaluation of new drug treatments for juvenile idiopathic arthritis: etanercept.
by: Cummins, C, et al.
Published: (2002)

Effect of Substrate Reduction Therapy in Comparison to Enzyme Replacement Therapy on Immune Aspects and Bone Involvement in Gaucher Disease
by: Renuka P. Limgala, et al.
Published: (2020-03-01)

The probability of cost-effectiveness
by: Stevens John W, et al.
Published: (2002-03-01)

Effectiveness and safety of nicotine replacement therapy assisted reduction to stop smoking: Systematic review and meta-analysis
by: Moore, D, et al.
Published: (2009)

Effectiveness and safety of nicotine replacement therapy assisted reduction to stop smoking: systematic review and meta-analysis.
by: Moore, D, et al.
Published: (2009)

Evaluation of the Nutritional Status of Gaucher Disease Type I Patients under Enzyme Replacement Treatment
by: Paola Iaccarino Idelson, et al.
Published: (2022-08-01)

'Cut down to quit' with nicotine replacement therapies in smoking cessation: a systematic review of effectiveness and economic analysis.
by: Wang, D, et al.
Published: (2008)

'Cut down to quit' with nicotine replacement therapies in smoking cessation: a systematic review of effectiveness and economic analysis.
by: Wang, D, et al.
Published: (2008)

Real-Life Experience with Oral Eliglustat in Patients with Gaucher Disease Previously Treated with Enzyme Replacement Therapy
by: Majdolen Istaiti, et al.
Published: (2022-10-01)

a-Synuclein and lipids in erythrocytes of Gaucher disease carriers and patients before and after enzyme replacement therapy.
by: Marina Moraitou, et al.
Published: (2023-01-01)

a-Synuclein and lipids in erythrocytes of Gaucher disease carriers and patients before and after enzyme replacement therapy
by: Marina Moraitou, et al.
Published: (2023-01-01)

Nicotine replacement therapy. Authors respond to criticism that treatment is ineffective.
by: Aveyard, P, et al.
Published: (2009)

Clinical effectiveness and cost-effectiveness of different models of managing long-term oral anticoagulation therapy: a systematic review and economic modelling
by: M Connock, et al.
Published: (2007-10-01)

Gaucher Disease and Gaucher Cells
by: Sevgi Gözdaşoğlu
Published: (2015-05-01)

Methadone and buprenorphine for the management of opioid dependence: a systematic review and economic evaluation.
by: Connock, M, et al.
Published: (2007)

Methadone and buprenorphine for the management of opioid dependence: a systematic review and economic evaluation.
by: Connock, M, et al.
Published: (2007)

Methadone and buprenorphine for the management of opioid dependence: A systematic review and economic evaluation
by: Connock, M, et al.
Published: (2007)

Palivizumab and the importance of cost effectiveness
by: Teale, A, et al.
Published: (2009)

Review of statistical methods for analysing healthcare resources and costs.
by: Mihaylova, B, et al.
Published: (2011)

Polyhydroxylated bicyclic isoureas and guanidines are potent glucocerebrosidase inhibitors and nanomolar enzyme activity enhancers in Gaucher cells.
by: Trapero, A, et al.
Published: (2011)

Gaucher Cells or Pseudo-Gaucher Cells: That's the Question
by: Deniz Gören Şahin, et al.
Published: (2014-12-01)

Gaucher's disease management protocol
by: E. A. Lukina, et al.
Published: (2022-11-01)

The clinical effectiveness and cost-effectiveness of riluzole for motor neurone disease: a rapid and systematic review.
by: Stewart, A, et al.
Published: (2001)

The clinical effectiveness and cost-effectiveness of riluzole for motor neurone disease: A rapid and systematic review
by: Stewart, A, et al.
Published: (2001)

Structural comparison of differently glycosylated forms of acid-beta-glucosidase, the defective enzyme in Gaucher disease.
by: Brumshtein, B, et al.
Published: (2006)

Neuropathological Features of Gaucher Disease and Gaucher Disease with Parkinsonism
by: Makaila L. Furderer, et al.
Published: (2022-05-01)

Gaucher disease.
by: Butters, T
Published: (2007)

Alpha-Synuclein mRNA Level Found Dependent on L444P Variant in Carriers and Gaucher Disease Patients on Enzyme Replacement Therapy
by: Paweł Dubiela, et al.
Published: (2023-04-01)

High-Dose Ambroxol Therapy in Type 1 Gaucher Disease Focusing on Patients with Poor Response to Enzyme Replacement Therapy or Substrate Reduction Therapy
by: Majdolen Istaiti, et al.
Published: (2023-04-01)

Ichthyosis as a manifestation of fetal gaucher
by: Francisco A. Palazón-Rico, et al.
Published: (2023-11-01)

Reply to Mistry et al. The Two Substrate Reduction Therapies for Type 1 Gaucher Disease Are Not Equivalent. Comment on “Hughes et al. Switching between Enzyme Replacement Therapies and Substrate Reduction Therapies in Patients with Gaucher Disease: Data from the Gaucher Outcome Survey (GOS). <i>J. Clin. Med.</i> 2022, <i>11</i>, 5158”
by: Derralynn A. Hughes, et al.
Published: (2023-06-01)

A systematic review of the effectiveness of adalimumab, etanercept and infliximab for the treatment of rheumatoid arthritis in adults and an economic evaluation of their cost-effectiveness
by: Chen, Y, et al.
Published: (2006)

A systematic review of the effectiveness of adalimumab, etanercept and infliximab for the treatment of rheumatoid arthritis in adults and an economic evaluation of their cost-effectiveness.
by: Chen, Y, et al.
Published: (2006)